The big health news Friday was that a botched drug trial in France had left four people with “irreversible” brain damage. One man is now brain dead and at least five others have been hospitalized, according to the latest reports.
Before details about the trial drug could be confirmed, AFP, France’s largest news agency, quoted an unnamed source “close to the case” who claimed the painkiller under trial contained cannabis. The story spiraled from there, picked up by panicked news media in France and the U.K. and spreading across the Internet.
RT dubbed the clinical trial “cannabis-laced.” Vice News screamed that “The Drug Trial of a Cannabis Painkiller Has Left One Person Brain Dead.”
Let’s be clear: That’s not true.
Shortly after the news broke, French Health Minister Marisol Touraine began correcting erroneous reports. The drug being tested, she said, contains neither cannabis nor cannabis derivatives.
Developed by the Portuguese pharmaceutical company Bial and tested in France by Biotrial, the drug in question is intended to address mood, anxiety and motor problems linked to neurodegenerative diseases. It works by affecting the endocannabinoid system, a set of brain receptors that cannabis interacts with. But there are other known substances, beyond cannabis, that affect the endocannabinoid system.
Media outlets quickly revised their headlines and stories, but the damage had been done. When it comes to cannabis, deeply-rooted fears have a tendency to seek out reinforcing evidence, no matter how erroneous that evidence may turn out to be. Pairing “cannabis drug” with “brain damage” creates a sticky meme that’s tough to un-stick.
Here’s the story you’re not hearing. There’s currently a scramble going on among researchers and pharmaceutical companies to develop non-cannabis drugs that affect the endocannabinoid system. FAAH and MAGL inhibitors in particular have shown promise as non-cannabis enzymes that could interact with the endocannabinoid system to produce healing results. Bial’s experimental drug could be part of that effort — or not. We don’t know enough about the trial drug yet to say for sure.
All of this begs the question: Why develop non-cannabis drugs when the plant is already available? One possibility: Proprietary drugs and patents. If you invent it and patent it, you own it. Nobody owns Charlotte’s Web or Harlequin.
La Jolla, California-based Abide Therapeutics, for instance, is developing a small-molecule inhibitor that interacts with the body’s endocannabinoid system and could potentially treat pain and neuroinflammation. (To be clear: Abide has no connection to the news out of France.) You can read more about Abide’s effort here.
We’ll continue to follow the story out of France as it develops, and we’ll also continue to look into developments in endocannabinoid research, both cannabis-related and non-cannabis-related. Stay tuned.
Where’s the Difference?
Even though most people who experience the cannabis high produced by THC find it to be pleasant and stimulating, for some reason medicine that makes you feel good while getting you well is frowned upon. Enter cannabidiol, commonly referred to as CBD, as a way to obtain the medicinal benefits of cannabis without the THC psychoactive effects making CBD an acceptable gateway drug to the world of cannabis.
CBD is a powerful cannabinoid with research showing it to be effective in reducing cancer cell growth, minimizing seizures and convulsions in children, decreasing inflammation, mitigating pain and providing therapeutic relief for many other ailments. This newfound interest in CBD has led to an explosion of CBD oils made from industrial hemp.
In terms of its molecular structure CBD is CBD is CBD—it’s the same molecule whether the CBD comes from hemp, cannabis or a test tube. Hemp generally has a CBD concentration around 3.5 percent CBD which is pretty low but the concentration of THC is even lower, usually less than 1 percent. Hemp meets the criteria of being low in THC, but its level of CBD is relatively low especially in comparison to certain cannabis strains, which have significantly higher amount of CBD than industrial hemp.
Whether the CBD comes from hemp or cannabis flowers is not the ultimate factor. The key factor is the process by which the CBD is extracted, concentrated and formulated. Cannabis strains such as Charlotte’s Web, Avidekel and ACDC are low in THC but high in CBD with up to a 20 percent CBD concentration level. By comparison, hemp’s typical 3.5 percent CBD concentration level is rather paltry.
Since the concentration of CBD is low in hemp, it requires large amounts of hemp to produce a small amount of CBD oil. The most efficient and least expensive way to extract the CBD oil is to use solvents, but dangerous solvent residues can remain in the CBD oil. In 2014, Project CBD, a California-based nonprofit dedicated to promoting and publicizing research into the medical uses of CBD, tested several CBD hemp oil products available to the public over the Internet and found significant levels of toxic solvent residues in random samples.
CBD oil extracted from industrial hemp is a thick tar-like substance that needs to be thinned with a compound such as propylene glycol. A widespread additive found in CBD vape oil cartridges, propylene glycol may convert to formaldehyde, a known carcinogen, when heated and inhaled.
Hexane, a solvent frequently used to extract CBDs from hemp, has been found by the Environmental Protection Agency (EPA) to be neurotoxic producing numbness in the extremities, muscular weakness, blurred vision, headache and fatigue, according to a official statement by the EPA.
Even if it is possible to produce solvent-free CBD oil from hemp, there is another problem in that industrial hemp is a bio-accumulator that naturally absorbs toxic substances from the soil. Hemp is such an efficient bio-accumulator that it was used at the Chernobyl Nuclear power plant after the meltdown because it is excellent at sucking up heavy metals and radiation, according to McGraw Hill Education. Great for healing the earth, but not for healing humans.
“The whole effort to harness CBD from industrial hemp is fraught with challenges that are made more difficult by the fact that fiber hemp plants with high amounts of CBD by dry weight—like the ACDC cannabis strain—are not yet available for industrial grows.”
Martin Lee, co-founder and Director of Project CBD, summarizes the problems of obtaining CBD from hemp. “The whole effort to harness CBD from industrial hemp is fraught with challenges that are made more difficult by the fact that fiber hemp plants with high amounts of CBD by dry weight—like the ACDC cannabis strain—are not yet available for industrial grows.”
There are other considerations as well. One of the most important is that CBD by itself does not work as well as CBD in conjunction with THC. In what is known as the entourage effect, the medical efficacy of CBD is enhanced in the presence of THC. The proper ratio of CBD to THC varies from person to person, but as Martin Lee points out “the best ratio of THC to CBD is often the most THC a person can comfortably handle.”
The bottom line is since hemp is so low in THC and other cannabis components, you don’t get much of an entourage effect when you use hemp oil as when you are using oil derived from a CBD-rich cannabis plant.
If certain cannabis flowers are so much better for producing CBD, then why all this fuss over industrial hemp? Rather than anything to do with medical science, it has everything to do with the illegal status of cannabis.
The manufacturers of CBD oil from hemp claim that it is legal to market their products as a dietary supplement even though the Food and Drug Administration (FDA) has refused to recognize hemp-derived CBD oil as a dietary supplement. The FDA singled out for criticism CBD oil producers for making unsubstantiated medical claims about treating pain, spasms, cancer and other ailments. The FDA has never approved CBD as a supplement for any kind of medical use.
Under current state medical marijuana laws, the only way a CBD-infused oil product—derived from hemp or cannabis—can be used legally for therapeutic purposes would be for it to be grown, harvested, processed and consumed by a certified patient in a state that has legalized medical cannabis. That is not the case with products made from CBD hemp oil imported from abroad which remain illegal under both federal and state laws.
For many reasons, CBD-rich cannabis is a better source of CBD than industrial hemp. The only reason CBD derived from hemp is gaining any notoriety is as an attempted end-run around federal law. When cannabis prohibition is ended and cannabis is treated like any other agricultural product, CBD will be extracted from the best source of cannabidiol—CBD-rich cannabis. The need to derive CBD from industrial hemp will end.
Medical research suggests that cannabis may help improve mood, but users also seem to suffer higher rates of depression.
Marijuana is sometimes referred to as ‘green Prozac’ due to the fact that many users find it helpful in lifting their spirits. But can it actually be an effective treatment for depression?
Interestingly, the idea that cannabis can be used to improve mood goes back hundreds of years. And many people today still agree.
“A lot of people report using cannabis effectively to treat depression,” says Zachary Walsh, an assistant professor of psychology at the University of British Columbia who heads a research lab focused on marijuana and mental health.
But whether cannabis has actually been proven to help with depression can’t be answered with a simple yes or no. The answer is more complicated because there are different types of depression, explains Walsh.
Generally speaking, depression is defined as the feeling of sadness or hopelessness over an extended period of time.
Studies on Marijuana and Depression
For depression that is caused by chronic stress, components of marijuana may be an effective treatment, according to a 2015 study by University of Buffalo scientists. The findings showed that stress caused a decrease in cannabis-like molecules naturally found in the brain, leading to behavior that mimicked depression.
Another study published in 2007 by a team at McGill University showed that administering low doses of THC could work like an antidepressant by increasing serotonin. However, in high dosages, THC decreased serotonin and seemed to worsen depression.
“These findings confirm what has been reported by people who smoke cannabis,” explains Dr. Gabriella Gobbi, who co-authored the McGill study. “Often it produces euphoria, calmness, sociability, but in other circumstances it can produce bad dreams and negative feelings.”
Overall there hasn’t been enough research in the field, Dr. Gobbi says, adding that the type of research needed to confirm whether marijuana can effectively treat depression is quite complex.
“Not only do we have to determine the dose-effect of cannabis on depressive people, but also which kind of cannabinoid may have a positive effect on mood.”
Cannabinoids are a class of molecules found in cannabis, which include THC and CBD. Over 60 different cannabinoids have been identified in marijuana, making it difficult to determine the drug’s overall effect on depression.
Higher Rates of Depression
While medical literature suggests that cannabis can improve mood, studies involving recreational users often show that people who use cannabis are more depressed, says Walsh.
“What those studies have noted is that they can’t really determine what comes first,” he explains. In other words: “Does cannabis cause depression? Do depressed people try to use cannabis to help with depression? Those are questions that are out there.”
An important factor in the answer could be the age of the person consuming cannabis.
According to research conducted by Dr. Gobbi in 2009, daily use of marijuana can cause depression and anxiety in teens.
“Cannabis, when consumed by adolescents, induces depression and anxiety later in adulthood, even if the people did not have any susceptibility for these mental diseases,” she says.
Cannabis vs. Antidepressants
While researchers can’t completely confirm if marijuana is effective for treating depression, Walsh points out that other medicines fall into the same problem.
He says that in some cases, typical antidepressants are no more effective than a placebo and have side effects that may be more severe than those of marijuana.
Dr. Gobbi explains that in order to declare a drug effective for a certain disease, it must go through different stages of clinical trials, which marijuana has not.
“If we want to take a rational approach about medicinal cannabis, we should go through systematic clinical studies and finally determine its efficacy in treating specific diseases and its safety compared to standard antidepressants,” she says.
Walsh agrees that further research should compare cannabis to commonly used antidepressants. “Then I think people can make the choice,” he concludes.
Behind strain names like Charlotte’s Web and Haleigh’s Hope are stories of children whose epileptic seizures were dramatically reduced through medical cannabis. But while evidence so far has been anecdotal, doctors this week are presenting the first scientific studies to back them up.
At the American Epilepsy Society meeting in Philadelphia, researchers are unveiling the results of trials testing the safety and efficacy of cannabidiol. The findings are largely promising. In the biggest study, the number of seizures went down by about half, on average, among children who completed the trial. Benefits for some continued even after the study was over.
“In the subsequent periods, which are very encouraging, 9 percent of all patients and 13 percent of those with Dravet Syndrome epilepsy were seizure-free,” Dr. Orrin Devinsky, the study’s lead author and a neurologist at the New York University Langone Medical Center, told NPR. “Many have never been seizure-free before.”
The data represent a significant step forward in legitimizing use of cannabis to treat epilepsy, a syndrome that in both children and adults causes debilitating seizures and can be especially difficult to treat. Patients sometimes exhaust traditional anti-seizure medications to no effect.
Despite the findings of CBD’s potential benefit in epilepsy treatment, the study results weren’t all good. In Devinsky’s three-month trial, 16 percent of participants withdrew due to adverse side effects or after deciding the treatment was ineffective. And in a yearlong study of 25 patients, one participant actually experienced more frequent seizures.
Participants in the studies didn’t smoke or vaporize cannabis flowers or concentrates. Rather, they consumed cannabidiol in the form of daily doses of purified extracts that had been derived from cannabis plants.
Parents across the country have turned to high-CBD strains after hearing about their sometimes life-changing benefits. Charlotte’s Web, for example, was developed in 2011 and popularized after it was used successfully to treat epileptic seizures in a Colorado girl, Charlotte Figi. While Figi’s story has encouraged lawmakers in some states to loosen regulations on high-CBD strains, many desperate parents still obtain the drug illegally. And because of a lack of scientific evidence to justify their decision, they often face stigma — not to mention the risk of jail time — for giving their children cannabis.
Until recently, clinical trials involving cannabis have been almost nonexistent. As a federally controlled substance, the drug has been impossible to study except with government approval. But as legalization spreads, information about the efficacy of cannabis in treating various ailments will likely become ever more available.
If you’re not familiar with Charlotte’s Web, watch this video about Charlotte Figi and her family:
Nearly a month after Mexico’s Supreme Court ruled in favor of the rights of four defendants to cultivate and consume marijuana without legal repercussion, the government has announced that it will take up the issue of nationwide legalization in the next legislative session.
The Associated Press reported earlier this week that Interior Secretary Miguel Angel Osorio Chong has revealed plans to hold a national debate on the concept of bringing the nation out of prohibitionary times. This discussion will include public hearings and a number of forums, some of which will be broadcast over the Internet.
Although Mexico has decriminalized small amounts of marijuana, lawmakers are expected to weigh in on exactly what might be expected in terms of health and public safety under a fully legal rule. The overall goal is to push the prohibitionist mentality into a more progressive thought process and eventually lead the country to support a taxed and regulated marketplace.
Unfortunately, on the heels of this major announcement, Mexico President Enrique Pena Nieto has come out in full force against the issue.
On Wednesday, during a press engagement for a new children’s program, Pena Nieto told the crowd that one of his kids recently asked him if they would soon be able “to light up a joint” in his presence. The president then proceeded to explain that he remains against marijuana legalization because he fears it will destroy the youth of the nation.
“I am not in favor of consuming or legalizing marijuana,” Pena Nieto said. “I am not in favor because it has been proven, demonstrated, that consuming this substance damages the health of children and youths.”
Yet, many supporters of the movement to establish a nationwide cannabis industry have suggested that ending cartel violence should be one of the primary motivations for moving in this direction. However, President Pena Nieto disagrees, arguing that, in no way, would legalization stop the cartels.
“It isn’t valid, and I don’t agree, that this legalization would make it easier to fight organized crime, by reducing the illicit income and profits from this activity,” he said. “That would beg the question, should we put the health of Mexican children and youths at risk in order to combat organized crime?”
What do you think? Could the legalization of cannabis destroy the youth?
Will 2015 be remembered as the year legal marijuana first encountered — and eventually figured out — its pesticide problem?
The national conversation surrounding pesticide application on cannabis blew up this year. The hot topic has made headlines in Oregon, Washington, New Hampshire, California and elsewhere — but nowhere was the conversation more heated and involved than in Colorado, the first U.S. state to start selling legal cannabis.
It began after more than 100,000 plants were put on hold because of pesticide concerns. Inspections were stepped-up in cultivation facilities. A lot of questions were asked — but not a lot of them had answers. The industry reacted to the changing landscape — but the industry also flexed its political muscle in an effort to delay state and city efforts to enact pesticide regulations.
My colleagues and I at The Denver Post and The Cannabist commissioned independent tests on marijuana concentrates, and the results — which showed high levels of banned pesticides in one popular brand, Mahatma — spurred a Denver Department of Environmental Health investigation thatrecalled Mahatma products, and now many others.
The pesticides-and-pot conversations in Colorado served as a gateway to other related issues. The Post learned that Colorado’s attorney general was investigating several marijuana businesses overconcerns the word “organic” in their names or advertising might be misleading to consumers. Colorado’s former agriculture commissioner said the marijuana industry “was the biggest obstacle we had” in devising any effective pesticide regulation. And more than two months after their first pot recall, Denver health officials started requiring marijuana companies that recall products tainted with unapproved pesticides to use their websites and social media accounts to alert consumers, who weren’t returning many of the recalled products, The Post learned.
Even though no sicknesses have yet been attributed to the use of these banned pesticides, a pair of marijuana users in Colorado — one of them a medical-card holder with a brain tumor — have sued the state’s largest pot grower for allegedly using a potentially dangerous pesticide on the pot they later purchased. The state proposed new rules that would further restrict which pesticides can be used to grow marijuana. Colorado Gov. John Hickenlooper issued an executive order telling state agencies that any marijuana grown with unapproved pesticides is a threat to public safety and should be removed from commerce and destroyed. TheU.S. Environmental Protection Agency put the onus on the makers of pesticides to prove their safety.
And meanwhile, the recalls of marijuana and pot products keep rolling. Because each recall of pesticide-tainted cannabis involves long lists of items associated with often-lengthy batch numbers, The Cannabist has compiled all of the available information in one place for readers concerned about the purity of their pot. So below you’ll find our reporting on each recall — as well as the city of Denver’s press releases on the recalls, which contain exact information to help users identify any tainted pot and cannabis products they might have.
Do you have pesticide-peppered pot in your stash? Find out now — and we will keep this list updated.
Earth Science Tech Announces Positive Interim results from Trial with Former Professional Football Athletes Using ETST High Grade Hemp CBD (Cannabidiol)
Boca Raton, Nov. 19, 2015 (GLOBE NEWSWIRE) — BOCA RATON, FL / Earth Science Tech, Inc. (ETST) (“ETST” or “the Company”), a unique biotechnology publicly traded company focused on nutraceuticals, bioceuticals and dietary supplements, announces interim results from phase 1 in introducing the ETST line of Nutraceutical and Bioceutical products to former professional athletes.
Approximately 2 weeks ago, ETST initiated its breakthrough trial study involving former professional football players using its Hemp CBD Oil. On the first day participants answered a number of questions scaling the intensity of various pain symptoms. They were all given doses of high potency Hemp CBD Oil to administer for 30 days two times a day. On day 15, the participants answered another series of questions scaling their pain levels. These preliminary results suggest a marked improvement in the participants’ pain levels.
The Former players and current candidates will be requested to submit a report of their affected physical and mental health at the conclusion of this trial. ETST is very excited about the future health implications suggested by these initial results. Although this is a first step on a long road, ETST looks forward to conducting future trial studies with former professional athletes.
ETST High Grade Hemp CBD is derived from imported 100% industrial hemp. ETST High Grade Hemp CBD Products contain hundreds of micronutrients (phytonutrients). These include Terpenoids, Essential Oils and Antioxidants. The most dynamic are a group of compounds called Cannabinoids that have been found to exist in Hemp and the human body. In addition to the cannabinoids present in our industrial hemp oil extracts, there are also many other types of natural molecules and “plant” chemical compounds such as amino acids, sugars, vitamins, fatty acids (including omega 3 & 6), flavanoids, ketones, nitrogenous compounds, alkanes, alcohols, glycosides, pigments, hemp seed oil, water, and terpenes. The most common terpenes in our CBD oils are Beta-caryophyllene, Caryophyllene Oxide, Myrcene, Terpinolene, Bisabolol, Pinene, Nerolidol, Ocimene and Phytol. Hemp oil contains more essential fatty acids than any other plant.
To view Scientific Research and Data on Earth Science Tech (ETST) High Grade Hemp CBD (Cannabidiol) please visit http://www.earthsciencetech.com/scientific-research.
ETST invites all interested parties to contact the company at firstname.lastname@example.org in order to secure its “High Grade Hemp CBD (Cannabidiol) Oil” in bulk for wholesale, resale or distribution. From product formulating, mixing, labeling and launching ETST can do it all. ETST is always open to forming new strategic partnerships, joint ventures and/or supplying vendors, resellers and third party distribution companies with its High Grade Hemp CBD (Cannabidiol) Oil/Products at wholesale prices in order to better help supply consumers as well as the health and wellness markets on a large scale. You can view, research and purchase small quantities or bottles of ETST High Grade CBD (Cannabidiol) Rich Hemp Oil at http://www.earthsciencetech.com/cbd-rich-hemp-oil.
ETST is focused on the science, research and studies of its High Grade Hemp CBD Oil as a health and wellness, nutraceutical and dietary supplement. In order to assure the public that ETST provides the best High Grade Hemp CBD (Cannabidiol) Oil, we continue to focus on providing the public with sound scientific research and keeping the public informed on the progression of studies being done on our Hemp CBD products. ETST has engaged the expertise of a leading USA independent biological company and has been doing scientific research and studies with a University. Science is what will progress the future of ETST High Grade Hemp CBD (Cannabidiol) Oil and its products. Cannabidiol (CBD) is a naturally occurring constituent of industrial hemp oil. It is the most abundant non-psychoactive cannabinoid in hemp and is commonly used as a dietary supplement to support general wellness. ETST hemp derived, high CBD, full-spectrum phyto-cannabinoid oil blends are made from top quality, Grade-A European hemp cultivars, grown in pristine soil in choice European locations. ETST High Grade Hemp CBD oils are constantly analyzed for their purity and purity from potential contaminants. ETST encourages researching cannabidiol (CBD) from reliable informational sources to see what is being investigated and discussed about CBD oil. Numerous properties and benefits of CBD are being investigated at academic research centers in the United States and elsewhere. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products.
Humans are designed with a built-in Endocannabinoid System (ECS): Research shows that many scientists believe cannabinoids work synergistically to support the whole human endo-cannabinoid system (internal and natural human cannabinoid system). It is your body’s way of communicating with itself and properly regulating the way every other body system functions from your brain to your toes. The Endocannabinoid System (ECS) has shown to control pain sensation, appetite, temperature regulation, stress reactivity, immune function, and sleep as well as other processes. Even more interesting is that muscle and fat tissue also utilize these receptors to control their processes. Consumers should think of the Endocannabinoid System as one of the body’s main control and command centers for tweaking your metabolism’s ability to react and adapt to the world around it. Like many other nutrients in our diet, Cannabinoids can become exhausted and in need of steady dietary replenishment. Scientific studies and data show that Hemp CBD (Cannabidiol) Oil as well as all micronutrients (phytonutrients) and phyto-cannabinoids found in the oil work in harmony with the human body’s own endocannabinoid system making a positive effect for overall wellness. Hemp oil contains CBD — a non-psychoactive compound of the plant. There are millions of hemp oil consumers around the world and this number is rapidly rising with an increasing number of reports and studies showing a variety of benefits of hemp oil.
ETST High Grade Hemp CBD (Cannabidiol): ETST High Grade Hemp CBD (Cannabidiol) Oil is formulated using a wide array of cutting-edge technologies. ETST’s High Grade Hemp CBD Oil is all-natural and derived completely from the federally legal industrial hemp plant. Industrial Hemp (Hemp) is not marijuana and will not get you ‘high’ and it does not require a medical license of any kind to authorize purchase. It is lab tested multiple times during the manufacturing process, from seed to shelf. This also includes being tested for CBD content, other Cannabinoid content, yeast/mold/fungus, and bacteria like E. coli to ensure safety and top quality. ETST believes that Hemp CBD Oil awareness today is where Omega 3 and Omega 6 fatty acids were 15 to 20 years ago. One of ETST’s pertinent objectives is to help consumers Worldwide with their overall wellness through advanced formulations with its High Grade Hemp CBD (Cannabidiol) Oil and other cutting edge nutraceuticals and dietary supplements. Hemp CBD Oil is poised to be the most renowned and effective natural compound and botanical alternative introduced to the nutritional and dietary supplement industry in decades. Consumers worldwide desperately need more effective safe botanical alternatives to help them with their overall health and internal wellness. Modern science has identified over 400 phytonutrients in various parts of the industrial hemp plant. These include hundreds of Terpenoids, Essential Oils and Antioxidants but perhaps the most dynamic are a group of 80 compounds called Cannabinoids that are exclusively found in Hemp and one other place; our bodies. There are roughly 80 different phyto-cannabinoids, most prominently CBD, CBC, CBG, CBN, and most likely others yet to be effectively identified. In addition to the cannabinoids present in High Grade Hemp CBD (Cannabidiol) Oil extracts, there are also many other types of natural molecules such as amino acids, fatty acids, flavonoids, ketones, nitrogenous compounds, alkanes, alcohols, glycosides, pigments and terpenes among other things. The most common terpenes in our Hemp CBD oils are Beta-caryophyllene, Caryophyllene Oxide, Myrcene, Terpinolene, α Bisabolol, α Pinene, Nerolidol, Ocimene and Phytol.
About Earth Science Tech, Inc. (ETST): Earth Science Tech (www.earthsciencetech.com) is a publicly traded (symbol: ETST) unique Science based Biotechnology company focused on cutting edge Nutraceuticals, Bioceuticals, Phytoceuticals and Cosmeceuticals for the Health, Wellness and Alternative Medicine Markets to help improve the quality of life for Consumers Worldwide. ETST is also dedicated to providing Natural Alternatives to prescription medications through the use of its cutting edge Nutritional and Dietary Supplements. This may include products such as its High Grade Hemp CBD (Cannabidiol) Oil, Vitamins, Minerals, Herbs, Botanicals, Personal Care Products, Homeopathies, Functional Foods and other products. These products may be in various formulations and delivery systems including (but not limited to) capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders, and whole herbs. ETST is focused on researching and developing innovative Hemp extracts and to make them accessible Worldwide. ETST plans to be the premier supplier of the highest quality and purity of High Grade Hemp CBD (Cannabidiol) Oil. ETST’s primary goal is to advance different High Quality Hemp extracts with a broad profile of Cannabinoids and additional natural molecules found in Industrial Hemp and to identify their distinct properties. The company is dedicated in offering its consumers the finest and purest quality All Natural-Organic Hemp CBD Oil while never compromising on quality. ETST High Grade Hemp CBD (Cannabidiol) Oil is classified as “food based” and therefore perfectly permissible in all 50 states and more than 40 countries. Cannabinoids (Cannabidiol/CBD) are natural constituents of the Hemp plant and CBD is derived from Hemp stalk and seed. Hemp oil is a well-known dietary supplement and the naturally occurring CBD possesses no psychoactive qualities and presents a continuing stream of overwhelming evidence of significant Wellness benefits. With no psychoactive ingredient, Hemp CBD Oil is a ready-for-market Hemp-based Nutraceutical. The United States Food and Drug Administration (FDA) currently considers non-THC hemp based cannabinoids, including CBD, to be “food based” and therefore saleable. These new non-psychoactive CBD-rich hemp oil products that ETST has geared up to market and distribute are beyond reproach. CBD (cannabidiol), a naturally occurring constituent of the Industrial Hemp plant, promotes and supports the nutritional health of aging bodies in particular. Source: US Government Patent #6,630,507 “Cannabinoids as antioxidants and neuroprotectants.” ETST does not grow, sell or distribute any substances that violate United States Law or the controlled substance act. ETST does sell and distribute hemp based products.
Make sure to visit ETST at:
ETST Corporate Website: www.earthsciencetech.com
ETST Twitter: https://twitter.com/earthsciencetec
ETST Facebook: https://www.facebook.com/Earthsciencetech
ETST Instagram: https://instagram.com/earthsciencetech
Investors Hangout: http://investorshangout.com/Earth-Science-Tech-Inc-ETST-68047/
As the cannabis industry continues to grow at a rapid pace, it can feel overwhelming to keep up-to-date with the constantly-changing federal and state regulations. Advertising regulations are especially strict, as many marketing platforms restrict or outright ban cannabis advertisements due to the substance’s federal status.
We put together a state-by-state guide to cannabis advertising regulations that should help cannabis businesses adhere to the guidelines set forth by both the state they’re operating in as well as any states in which they want to advertise. Be sure to check back constantly as we update this guide to reflect new changes and restrictions.
Click on a state to jump down to its list of cannabis advertising regulations:
Final advertising regulations for retail cannabis are to be determined. For more information, please refer to the Alaska Department of Health and Social Services Division of Public Health.
There are currently no advertising regulations for medical marijuana dispensaries in Arizona. For more information, please refer to the Rules & Statutes for the Arizona Medical Marijuana Program.
Refer to section 2525.5. of the Medical Marijuana Regulation and Safety Act:
(a) A person shall not distribute any form of advertising for physician recommendations for medical cannabis in California unless the advertisement bears the following notice to consumers:
NOTICE TO CONSUMERS: The Compassionate Use Act of 1996 ensures that seriously ill Californians have the right to obtain and use cannabis for medical purposes where medical use is deemed appropriate and has been recommended by a physician who has determined that the person’s health would benefit from the use of medical cannabis. Recommendations must come from an attending physician as defined in Section 11362.7 of the Health and Safety Code. Cannabis is a Schedule I drug according to the federal Controlled Substances Act. Activity related to cannabis use is subject to federal prosecution, regardless of the protections provided by state law.
(b) Advertising for attending physician recommendations for medical cannabis shall meet all of the requirements in Section 651. Price advertising shall not be fraudulent, deceitful, or misleading, including statements or advertisements of bait, discounts, premiums, gifts, or statements of a similar nature.
Refer to the Colorado Retail Marijuana Regulations:
R 1102 – Advertising General Requirement: No Deceptive, False or Misleading Statements
A Retail Marijuana Establishment shall not engage in Advertising that is deceptive, false, or misleading. A Retail Marijuana Establishment shall not make any deceptive, false, or misleading assertions or statements on any product, any sign, or any document provided to a consumer.
R 1104 –Advertising: Television
A. Television Defined. As used in this rule, the term “television” means a system for transmitting visual images and sound that are reproduced on screens, and includes broadcast, cable, on-demand, satellite, or internet programming. Television includes any video programming downloaded or streamed via the internet.
B. Television Advertising. A Retail Marijuana Establishment shall not utilize television Advertising unless the Retail Marijuana Establishment has reliable evidence that no more than 30 percent of the audience for the program on which the Advertising is to air is reasonably expected to be under the age of 21.
R 1105 –Advertising: Radio
A. Radio Defined. As used in this rule, the term “radio” means a system for transmitting sound without visual images, and includes broadcast, cable, on-demand, satellite, or internet programming. Radio includes any audio programming downloaded or streamed via the internet.
B. Radio Advertising. A Retail Marijuana Establishment shall not engage in radio Advertising unless the Retail Marijuana Establishment has reliable evidence that no more than 30 percent of the audience for the program on which the Advertising is to air is reasonably expected to be under the age of 21.
R 1106 –Advertising: Print Media
A Retail Marijuana Establishment shall not engage in Advertising in a print publication unless the Retail Marijuana Establishment has reliable evidence that no more than 30 percent of the publication’s readership is reasonably expected to be under the age of 21.
R 1107 –Advertising: Internet
A Retail Marijuana Establishment shall not engage in Advertising via the internet unless the Retail Marijuana Establishment has reliable evidence that no more than 30 percent of the audience for the internet web site is reasonably expected to be under the age of 21. See also Rule R 1114 – Pop-Up Advertising.
R 1108 – Advertising: Targeting Out-of-State Persons Prohibited.
A Retail Marijuana Establishment shall not engage in Advertising that specifically targets Persons located outside the state of Colorado.
R 1109 – Signage and Advertising: No Safety Claims Because Regulated by State Licensing Authority
No Retail Marijuana Establishment may engage in Advertising or utilize signage that asserts its products are safe because they are regulated by the State Licensing Authority.
R 1110– Signage and Advertising: No Safety Claims Because Tested by a Retail Marijuana Testing Facility
A Retail Marijuana Establishment may advertise that its products have been tested by a Retail Marijuana Testing Facility, but shall not engage in Advertising or utilize signage that asserts its products are safe because they are tested by a Retail Marijuana Testing Facility
R 1111– Signage and Advertising: Outdoor Advertising
A. Local Ordinances. In addition to any requirements within these rules, a Retail Marijuana Establishment shall comply with any applicable local ordinances regulating signs and Advertising.
B. Outdoor Advertising Generally Prohibited. Except as otherwise provided in this rule, it shall be unlawful for any Retail Marijuana Establishment to engage in Advertising that is visible to members of the public from any street, sidewalk, park or other public place, including Advertising utilizing any of the following media: any billboard or other outdoor general Advertising device; any sign mounted on a vehicle, any hand-held or other portable sign; or any handbill, leaflet or flier directly handed to any person in a public place, left upon a motor vehicle, or posted upon any public or private property without the consent of the property owner.
C. Exception. The prohibitions set forth in this rule shall not apply to any fixed sign that is located on the same zone lot as a Retail Marijuana Establishment and that exists solely for the purpose of identifying the location of the Retail Marijuana Establishment and otherwise complies with any applicable local ordinances
R 1112– Signage and Advertising: No Content That Targets Minors
A Retail Marijuana Establishment shall not include in any form of Advertising or signage any content that specifically targets individuals under the age of 21, including but not limited to cartoon characters or similar images.
R 1113 – Advertising: Advertising via Marketing Directed Toward Location-Based Devices
A Retail Marijuana Establishment shall not engage in Advertising via marketing directed towards location-based devices, including but not limited to cellular phones, unless the marketing is a mobile device application installed on the device by the owner of the device who is 21 year of age or older and includes a permanent and easy opt-out feature.
R 1114 – Pop-Up Advertising
A Retail Marijuana Establishment shall not utilize unsolicited pop-up Advertising on the internet.
R 1115 – Advertising: Event Sponsorship
A Retail Marijuana Establishment may sponsor a charitable, sports, or similar event, but a Retail Marijuana Establishment shall not engage in Advertising at, or in connection with, such an event unless the Retail Marijuana Establishment has reliable evidence that no more than 30 percent of the audience at the event and/or viewing Advertising in connection with the event is reasonably expected to be under the age of 21.
Sec. 21a-408-66. Marketing: prohibited conduct, statements and illustrations; commissioner review of advertisements
(a) There shall be no direct or indirect cooperative advertising between or among two or more of the following: a producer, dispensary facility personnel, or physician where such advertising has the purpose or effect of steering or influencing patient or caregiver choice with regard to their selection of a physician, dispensary or marijuana product.
(b) An advertisement for marijuana or any marijuana product shall not contain:
(1) Any statement that is false or misleading in any material particular or is otherwise in violation of the Connecticut Unfair Trade Practices Act, section 42-110b et seq., of the Connecticut General Statutes;
(2) any statement that falsely disparages a competitor’s products;
(3) any statement, design, or representation, picture or illustration that is obscene or indecent;
(4) any statement, design, representation, picture or illustration that encourages or represents the use of marijuana for a condition other than a debilitating medical condition;
(5) any statement, design, representation, picture or illustration that encourages or represents the recreational use of marijuana;
(6) any statement, design, representation, picture or illustration related to the safety or efficacy of marijuana unless supported by substantial evidence or substantial clinical data;
(7) any statement, design, representation, picture or illustration portraying anyone under the age of 18, objects suggestive of the presence of anyone under the age of 18, or contains the use of a figure, symbol or language that is customarily associated with anyone under the age of 18;
(8) any offer of a prize or award to a qualifying patient, primary caregiver or physician related to he purchase of marijuana or a certification for the use of marijuana; or
(9) any statement that indicates or implies that the product or entity in the advertisement has been approved or endorsed by the commissioner, department, the State of Connecticut or any person or entity associated with the State of Connecticut.
(c) Any advertisement for marijuana or a marijuana product shall be submitted to the commissioner at the same time as, or prior to, the dissemination of the advertisement.
(d) The submitter of the advertisement shall provide the following information in addition to the advertisement itself:
(1) A cover letter that:
(A) Provides the following subject line: Medical marijuana advertisement review Package for a proposed advertisement for [Brand Name];
(B) Provides a brief description of the format and expected distribution of the proposed advertisement; and
(C) Provides the submitter’s name, title, address, telephone number, fax number, and email address;
(2) An annotated summary of the proposed advertisement showing every claim being made in the advertisement and which references support each claim;
(3) Verification that a person identified in an advertisement as an actual patient or health care practitioner is an actual patient or health care practitioner and not a model or actor;
(4) Verification that a spokesperson who is represented as a real patient is indeed an actual patient;
(5) Verification that an official translation of a foreign language advertisement is accurate;
(6) Annotated references to support disease or epidemiology information, cross-referenced to the advertisement summary; and
(7) A final copy of the advertisement, including a video where applicable, in an acceptable format.
(e) Advertising packages that are missing any of the elements in subsection (g) of this section, or that fail to follow the specific details for submissions, shall be considered incomplete. If the department receives an incomplete package, it shall so notify the submitter.
(f) The commissioner may:
(1) Require a specific disclosure be made in the advertisement in a clear and conspicuous manner if the commissioner determines that the advertisement would be false or misleading without such a disclosure; or
(2) Make recommendations with respect to changes that are:
(A) Necessary to protect the public health, safety and welfare; or
(B) Consistent with dispensing information for the product under review.
(3) If appropriate and if information exists, recommend statements for inclusion in the advertisement to address the specific efficacy of the drug as it relates to specific disease states, disease symptoms and population groups.
Sec. 21a-408-67. Marijuana advertising; requirements for true statements and fair balance
(a) All advertisements for marijuana or marijuana products that make a statement relating to side effects, contraindications and effectiveness shall present a true statement of such information. When applicable, advertisements broadcast through media such as radio, television, or other electronic media shall include such information in the audio or audio and visual parts of the presentation.
(b) False or misleading information in any part of the advertisement will not be corrected by the inclusion of a true statement in another distinct part of the advertisement.
(c) An advertisement does not satisfy the requirement that it present a “true statement” of information relating to side effects, consequences, contraindications, and effectiveness if it fails to present a fair balance between information relating to side effects, consequences, contraindications and effectiveness in that the information relating to effectiveness is presented in greater scope, depth, or detail than is the information relating to side effects, consequences and contraindications, taking into account all implementing factors such as typography, layout, contrast, headlines, paragraphing, white space, and any other techniques apt to achieve emphasis.
(d) An advertisement is false, lacking in fair balance, or otherwise misleading if it:
(1) Contains a representation or suggestion that a marijuana strain, brand or product is better, more effective, useful in a broader range of conditions or patients or safer than other drugs or treatments including other marijuana strains or products, unless such a claim has been demonstrated by substantial evidence or substantial clinical experience;
(2) Contains favorable information or opinions about a marijuana product previously regarded as valid but which have been rendered invalid by contrary and more credible recent information;
(3) Uses a quote or paraphrase out of context or without citing conflicting information from the same source, to convey a false or misleading idea;
(4) Uses a study on individuals without a debilitating medical condition without disclosing that the subjects were not suffering from a debilitating medical condition;
(5) Uses data favorable to a marijuana product derived from patients treated with a different product or dosages different from those approved in Connecticut;
(6) Contains favorable information or conclusions from a study that is inadequate in design, scope, or conduct to furnish significant support for such information or conclusions; or
(7) Fails to provide adequate emphasis for the fact that two or more facing pages are part of the same advertisement when only one page contains information relating to side effects, consequences and contraindications.
(e) No advertisement may be disseminated if the submitter of the advertisement has received information that has not been widely publicized in medical literature that the use of the marijuana product or strain may cause fatalities or serious damage.
Sec. 21a-408-68. Marijuana marketing; advertising at a dispensary facility; advertising prices
(a) A dispensary facility shall:
(1) Restrict external signage to a single sign no larger than 16 X 18 inches;
(2) Not illuminate a dispensary facility sign advertising a marijuana product at any time;
(3) Not advertise marijuana brand names or utilize graphics related to marijuana or paraphernalia on the exterior of the dispensary facility or the building in which the dispensary facility is located; and
(4) Not display marijuana and paraphernalia so as to be clearly visible from the exterior of a dispensary facility.
(b) A producer shall not advertise the price of its marijuana except that it may make a price list available to a dispensary facility.
Refer to the Delaware Medical Marijuana Act:
(k) No person may advertise medical marijuana sales in print, broadcast, or by paid in-person solicitation of customers. This shall not prevent appropriate signs on the property of the registered compassion center, listings in business directories including phone books, listings in trade or medical publications, or the sponsorship of health or not-for-profit charity or advocacy events.
(l) A registered compassion center shall not share office space with nor refer patients to a physician.
(m) A physician shall not refer patients to a registered compassion center or registered designated caregiver, advertise in a registered compassion center, or, if the physician issues written certifications, hold any financial interest in a registered compassion center.
District of Columbia
5105.2 A medical marijuana certification provider shall include the following subjects in its education training program; which shall be submitted to the Department for approval:
(f) Advertising, promotion, and marketing of medical marijuana;
CHAPTER 58 ADVERTISING
5800 SIGN ADVERTISING
5800.1 Advertisements relating to the prices of medical marijuana shall not be displayed in the window of a registered establishment.
5800.2 Advertisements relating to medical marijuana shall not be displayed on the exterior of any window or on the exterior or interior of any door.
5800.3 No sign advertising medical marijuana on the exterior or visible from the exterior of any registered establishment or elsewhere in the District shall be illuminated at any time.
Advertising regulations for Florida authorized distribution centers are to be determined. For more information, please refer to the Compassionate Medical Cannabis Act of 2014.
Georgia’s medical marijuana advertising regulations are to be determined. For more information, please refer to House Bill 1.
Final dispensary regulations are to be determined. For more information, please visit the State of Hawaii Department of Health Medical Marijuana Registry Program.
TITLE 68: PROFESSIONS AND OCCUPATIONS
Section 1290.455 Dispensary Advertisements
a) No registered dispensing organization shall place or maintain, or cause to be placed or maintained, an advertisement of cannabis or a cannabis-infused product in any form or through any medium:
1) Within 1,000 feet of the perimeter of a school grounds, playground, recreation center or facility, child care center, public park or library, or any game arcade admission to which is not restricted to persons age 21 years or older;
2) On or in a public transit vehicle or public transit shelter; or
3) On or in a publicly-owned or-operated property.
b) This Section does not apply to a noncommercial message.
There are currently no advertising regulations for registered dispensaries or caregivers in Maine. For more information, please refer to the Rules Governing the Maine Medical Use of Marijuana Program.
Final medical marijuana regulations are to be determined. For more information, please refer to the Maryland Laws & Regulations FAQ.
(L) Marketing and Advertising Requirements
(1) A Registered Marijuana Dispensary (RMD) may develop a logo to be used in labeling, signage, and other materials. Use of medical symbols, images of marijuana, related paraphernalia, and colloquial references to cannabis and marijuana are prohibited from use in this logo.
(2) RMD external signage shall not be illuminated except for a period of 30 minutes before sundown until closing, and shall comply with local requirements regarding signage, provided however that the Department may further specify minimum signage requirements. Neon signage is prohibited at all times.
(3) A RMD shall not display on the exterior of the facility advertisements for marijuana or any brand name, and may only identify the building by the registered name.
(4) A RMD shall not utilize graphics related to marijuana or paraphernalia on the exterior of the RMD or the building in which the RMD is located.
5) A RMD shall not advertise the price of marijuana, except that it shall provide a catalogue or a printed list of the prices and strains of marijuana available at the RMD to registered qualifying patients and personal caregivers upon request.
(6) Marijuana, Marijuana Infused Products (MIPs), and associated products shall not be displayed or clearly visible to a person from the exterior of a RMD.
(7) A RMD shall not produce any items for sale or promotional gifts, such as T-shirts or novelty items, bearing a symbol of or references to marijuana or MIPs, including the logo of the RMD.
(8) All advertising materials and materials produced by a RMD and disseminated pursuant to 105 CMR 725.105(K) or (L) are prohibited from including:
(a) Any statement, design, representation, picture, or illustration that encourages or represents the use of marijuana for any purpose other than to treat a debilitating medical condition or related symptoms;
(b) Any statement, design, representation, picture, or illustration that encourages or represents the recreational use of marijuana;
(c) Any statement, design, representation, picture, or illustration related to the safety or efficacy of marijuana unless supported by substantial evidence or substantial clinical data with reasonable scientific rigor, which shall be made available upon the request of a registrant or the Department; or
(d) Any statement, design, representation, picture, or illustration portraying anyone under 18 years of age.
(9) Inside the RMD, all marijuana shall be kept in a limited access area inaccessible to any persons other than dispensary agents, with the exception of displays allowable under 105 CMR 725.105(L)(10). Inside the RMD, all marijuana shall be stored in a locked, access controlled space in a limited access area during non-business hours.
(10) A RMD may display, in secure, locked cases, no more than one sample of each product offered for sale. These display cases may be transparent.
(11) The Department shall maintain and make available a list of all RMDs, their dispensing location, and their contact information.
There are currently no restrictions on advertising (although there are restrictions on medical marijuana dispensaries) in Michigan. For more information, please refer to the Michigan Medical Marihuana Program.
There are currently no restrictions on advertising for medical marijuana manufacturers and distribution centers. For more information, please refer to Minnesota Statutes 2012, Subdivision 22, Medical use of cannabis data.
Refer to the Montana Code Annotated 2015 – Montana Marijuana Act:
50-46-341. Advertising prohibited. Persons with valid registry identification cards may not advertise marijuana or marijuana-related products in any medium, including electronic media.
Refer to Chapter 453A – Medical Use of Marijuana:
NAC 453A.402 Approval required before use of name, logo, sign and advertisement. (NRS 453A.370) A medical marijuana establishment shall not use:
1. A name or logo unless the name or logo has been approved by the Administrator of the Division; or
2. Any sign or advertisement unless the sign or advertisement has been approved by the Administrator of the Division.
(Added to NAC by Div. of Pub. & Behavioral Health by R004-14, 3-28-2014, eff. 4-1-2014)
The department shall adopt rules, pursuant to RSA 541-A, governing alternative treatment centers and the manner in which it shall consider applications for registration certificates for alternative treatment centers, including, but not limited to:
(12) Advertising restrictions, including a prohibition of misrepresentation and unfair practices.
Leafly has reached out to officials with the State of New Jersey Department of Health’s Medicinal Marijuana Program and are waiting for more comprehensive information on advertising regulations.
For more information, please refer to the state’s Medicinal Marijuana Program.
New Mexico currently does not have advertising regulations for medical marijuana dispensaries. For more information, please see the Licensing Requirements for Producers, Couriers, Manufacturers, and Laboratories.
§1004.16 Medical marihuana marketing and advertising by registered organizations. Restricts the marketing and advertising of medical marihuana.
(d) All advertisements, regardless of form, for approved medical marihuana products that make a statement relating to effectiveness, side effects, consequences, and contraindications shall present a true and accurate statement of such information.
(e) An advertisement does not satisfy the requirement that it presents a “true and accurate statement” of information relating to effectiveness, side effects, consequences, and contraindications if it fails to present a fair balance between information relating to effectiveness, side effects, consequences, and contraindications in that the information relating to effectiveness is presented in greater scope, depth, or detail than is the information relating to side effects, consequences and contraindications, taking into account all implementing factors such as typography, layout, contrast, headlines, paragraphing, white space, and any other techniques apt to achieve emphasis.
(f) An advertisement is false, lacking in fair balance, or otherwise misleading if it:
(1) contains a representation or suggestion that one marihuana brand or form is better, more effective, useful in a broader range of conditions or patients or safer than other drugs or treatments including other marihuana brands or forms, unless such a claim has been demonstrated by substantial scientific or clinical experience;
(2) Contains favorable information or opinions about a marihuana product previously regarded as valid but which have been rendered invalid by contrary and more credible recent information;
(3) Uses a quote or paraphrase out of context or without citing conflicting information from the same source, to convey a false or misleading idea;
(4) Uses a study on persons without a debilitating medical condition without disclosing that the subjects were not suffering from a debilitating medical condition;
(5) Uses data favorable to a marihuana product derived from patients treated with a different product or dosages different from those recommended in New York State;
(6) Contains favorable information or conclusions from a study that is inadequate in design, scope, or conduct to furnish significant support for such information or conclusions; or
(7) Fails to provide adequate emphasis for the fact that two or more facing pages are part of the same advertisement when only one page contains information relating to side effects, consequences and contraindications.
(g) False or misleading information in any part of the advertisement shall not be corrected by the inclusion of a true statement in another distinct part of the advertisement.
(h) An advertisement for any approved medical marihuana product shall not contain:
(1) any statement that is false or misleading;
(2) any statement that falsely disparages a competitor’s products;
(3) any statement, design, or representation, picture or illustration that is obscene or indecent;
(4) any statement, design, representation, picture or illustration that encourages or represents the use of marihuana for a condition other than a serious condition as defined in subdivision seven of section thirty-three hundred sixty of the public health law;
(5) any statement, design, representation, picture or illustration that encourages or represents the recreational use of marihuana;
(6) any statement, design, representation, picture or illustration related to the safety or efficacy of marihuana, unless supported by substantial evidence or substantial clinical data;
(7) any statement, design, representation, picture or illustration portraying anyone under the age of 18, objects suggestive of the presence of anyone under the age of 18, or containing the use of a figure, symbol or language that is customarily associated with anyone under the age of 18;
(8) any offer of a prize, award or inducement to a certified patient, designated caregiver or practitioner related to the purchase of marihuana or a certification for the use of marihuana; or
(9) any statement that indicates or implies that the product or entity in the advertisement has been approved or endorsed by the commissioner, department, New York State or any person or entity associated with New York State provided that this shall not preclude a factual statement that an entity is a registered organization.
(i) Any advertisement for an approved medical marihuana product shall be submitted to the department at least 30 business days prior to the public dissemination of the advertisement.
(j) The submitter of the advertisement shall provide the following information to the department in addition to the advertisement itself:
(1) A cover letter that:
(i) provides the following subject line: Medical marihuana advertisement review package for a proposed advertisement;
(ii) provides a brief description of the format and expected distribution of the proposed advertisement; and
(iii) provides the submitter’s name, title, address, telephone number, fax number, and email address;
(2) an annotated summary of the proposed advertisement showing every claim being made in the advertisement and which references support for each claim;
(3) verification that a person identified in an advertisement as an actual patient or health care practitioner is an actual patient or health care practitioner and not a model or actor;
(4) verification that a spokesperson who is represented as an actual patient is indeed an actual patient;
(5) verification that an official translation of a foreign language advertisement is accurate;
(6) annotated references to support disease or epidemiology information, cross-referenced to the advertisement summary; and
(7) a final copy of the advertisement, including a video where applicable, in a format acceptable to the department.
(k) Advertising packages that are missing any of the elements in subdivision.
(j) of this section, or that fail to follow the specific instructions for submissions, shall be considered incomplete. If the department receives an incomplete package, it shall so notify the submitter.
(l) No advertisement may be disseminated if the submitter of the advertisement has received information that has not been widely publicized in medical literature that the use of any approved medical marihuana product may cause fatalities or serious damage to a patient.
(m) A registered organization, its officers, managers and employees shall not cooperate, directly or indirectly, in any advertising if such advertising has the purpose or effect of steering or influencing patient or caregiver choice with regard to the selection of a practitioner, or approved medical marihuana product.
(n) The department may:
(1) require a specific disclosure be made in the advertisement in a clear and conspicuous manner if the department determines that the advertisement would be false or misleading without such a disclosure; or
(2) require that changes be made to the advertisement that are:
(i) necessary to protect the public health, safety and welfare; or
(ii) consistent with dispensing information for the product under review.
(2) The function, duties, and powers of the commission in sections 3 to 70 of this Act include the following:
(g) To regulate and prohibit any advertising by manufacturers, processors, wholesalers or retailers of marijuana items by the medium of newspapers, letters, billboards, radio or otherwise.
Q. What signage must dispensaries display at their sites?
NOTE: All required signage is available on the Forms and Signage page.
A registered dispensary must post the applicable entry sign on the exterior of the dispensary in a conspicuous location that can be easily seen by the public from outside the dispensary at any point of public entry, in bold, 80 point Times New Roman font.
- If a dispensary is only transferring marijuana and immature plants to OMMP patients and caregivers, the dispensary must post a sign that reads: “Medical Marijuana Patients Only.”
- If a dispensary has properly notified the Authority that it intends to sell limited marijuana retail products, the dispensary must post signs that read: “Medical Marijuana Patients and Persons 21 and Older Permitted” and “NO PERSON UNDER 21 PERMITTED ON THE PREMISES WITHOUT AN OMMP CARD.”
Point of Sale Signage
A registered dispensary that has notified the Oregon Health Authority that it is conducting retail sales must also post the following signs at the point of sale:
- Pregnancy Warning Poster
- Poisoning Prevention Poster
- A color copy of the “Educate Before You Recreate” poster (Source:whatslegaloregon.com).
Marijuana Information Card
Distribute to each individual at the time of sale a Marijuana Information Card, prescribed by the Authority, measuring 3.5 inches high by 5 inches.
There are currently no advertising regulations for medical marijuana dispensaries in Rhode Island. For more information, please refer to the Edward O. Hawkins and Thomas C. Slater Medical Marijuana Act.
There are currently no advertising regulations for dispensaries in Vermont. For more information, please refer to the Vermont Marijuana Registry.
(1) Advertising by retail licensees. The board limits each retail licensed premises to one sign identifying the retail outlet by the licensee’s business name or trade name that is affixed or hanging in the windows or on the outside of the premises that is visible to the general public from the public right of way. The size of the sign is limited to sixteen hundred square inches.
(2) General. All marijuana advertising and labels of useable marijuana and marijuana-infused products sold in the state of Washington may not contain any statement, or illustration that:
(a) Is false or misleading;
(b) Promotes over consumption;
(c) Represents the use of marijuana has curative or therapeutic effects;
(d) Depicts a child or other person under legal age to consume marijuana, or includes:
(i) Objects, such as toys, characters, or cartoon characters suggesting the presence of a child, or any other depiction designed in any manner to be especially appealing to children or other persons under legal age to consume marijuana; or
(ii) Is designed in any manner that would be especially appealing to children or other persons under twenty-one years of age.
(3) No licensed marijuana producer, processor, or retailer shall place or maintain, or cause to be placed or maintained, an advertisement of marijuana, usable marijuana, or a marijuana-infused product in any form or through any medium whatsoever:
(a) Within one thousand feet of the perimeter of a school grounds, playground, recreation center or facility, child care center, public park, library, or a game arcade admission to which it is not restricted to persons aged twenty-one years or older;
(b) On or in a public transit vehicle or public transit shelter; or
(c) On or in a publicly owned or operated property.
(4) Giveaways, coupons, and distribution of branded merchandise are banned.
(5) All advertising must contain the following warnings:
(a) “This product has intoxicating effects and may be habit forming.”;
(b) “Marijuana can impair concentration, coordination, and judgment. Do not operate a vehicle or machinery under the influence of this drug.”;
(c) “There may be health risks associated with consumption of this product.”; and
(d) “For use only by adults twenty-one and older. Keep out of the reach of children.”
While some people say we should wait and see, and others are saying now’s the time or it should already have happened, one thing is clear: There will be a debate on marijuana legalization during the upcoming legislative session.
It was during the last legislative session that Sen. David Zuckerman, P-Chittenden, introduced a bill to allow the possession, cultivation and sale of marijuana. Rep. Christopher Pearson, P-Burlington, introduced a parallel bill in the House that mirrors Zuckerman’s proposed legislation.
Both bills followed a state-commissioned study from the Rand Corporation that did not make any recommendations, but studied the potential impacts — from financial to health — of Vermont being the first state east of the Mississippi River to legalize marijuana, and the first state to ever legalize it through the legislative process rather than by a ballot initiative.
Zuckerman’s bill is actually one of 10 marijuana-related bills currently pending before lawmakers during the second half of the legislative biennium, with topics ranging from taxation and law enforcement to expansion of the state’s current medical marijuana laws and the packaging of edible marijuana products.
Motivations for legalization vary greatly among supporters, from those who see it as a civil liberties issue — what you do with your body is your own business — to the hypocrisy of alcohol being legal while marijuana is not. For others, the motivation is financial.
The Rand study projects that Vermont could collect anywhere from $20 million to $70 million annually from the taxation of marijuana, an attractive proposition as the state is looking at a projected $66 million budget shortfall. The bills from Zuckerman and Pearson outline how taxation might work.
Both bills call for an excise tax of $40 an ounce on processed marijuana, $15 an ounce for any other type of marijuana and $25 for each immature plant sold by a cultivator.
Rather than go directly into the state’s General Fund, the money raised from the taxes would support public initiatives to educate the public on the hazards of alcohol, tobacco and marijuana, criminal justice and substance abuse programs, law enforcement, and medical research on marijuana.
Exactly how much the state would stand to gain is anyone’s guess, with the Rand study saying Vermont would take in more revenue if it were the first state in the northeast to go the legalization route, an acknowledgment that legal marijuana would be a significant draw for many of the tens of millions of people who live within a day’s drive of Vermont.
During its 2015 fiscal year that ended in June, Colorado — which does not have the population density in adjacent states that Vermont has — collected $70 million in marijuana taxes.
Interstate trafficking is one of the issues raised in guidelines to states with legal marijuana from the U.S. Justice Department, which still considers it to be illegal. At the state level, lawmakers are looking to address a different kind of law enforcement issue: stoned driving.
Rep. Cynthia Browning, D-Arlington, has introduced legislation that would task the state’s Department of Health and the Department of Public Safety to establish standards to determine what constitutes impairment.
Currently, the Vermont State Police, for example, employ what they refer to as “drug recognition experts,” who make subjective judgments on the side of the road to determine if a driver is under the influence of marijuana. One lawmaker would like to create a more concrete test.
Rep. David Potter, D-West Rutland, is the sponsor of a bill that require drivers suspected of driving under the influence to submit to a saliva test. Current law states that a driver who travels Vermont’s roads has given consent to submit to a breath test, and the proposed legislation would expand that implied consent to include a saliva test.
The bill would make driving with any level of any drug in one’s system a crime; individuals with a prescription for a drug could use that prescription as an affirmative defense. A defendant would also have the right to have the saliva sample tested by an independent laboratory for analysis.
In 2004, the Legislature gave its consent for the therapeutic use of marijuana, and is today one of 23 states — plus the District of Columbia — to allow the practice.
However, Vermont has some of the highest thresholds to qualify for medical use, restricting prescriptions to people who suffer from what the law refers to as “debilitating medical conditions” such as AIDS, cancer or multiple sclerosis. The patient must also be under the care of the prescribing doctor for at least six months prior to receiving a prescription.
Rep. James Masland, D-Thetford, has introduced a bill that would add the diagnosis of post-traumatic stress disorder to the list of conditions that would allow a patient to receive a medical marijuana prescription.
Masland is also the co-sponsor of a bill introduced by Rep. George Till, D-Jericho, which would similarly add post-traumatic stress disorder as a qualifying diagnosis to receive medical marijuana. Additionally, however, Till’s bill would waive the requirement for a patient to be under the care of the prescribing doctor for six months provided the patient is a military veteran who has received a diagnosis of PTSD from the U.S. Department of Veterans’ Affairs.
Early conversation on marijuana legalization has taken up a fair amount of time on a relatively minor facet of the issue, and that is how to address marijuana-infused edible products. Scattered press reports from Colorado tell stories of people either ingesting too much for their own comfort, or unknowingly eating an edible that resembles something as benign as a cookie or cupcake.
Sen. Dick Sears, D-Bennington, has introduced a bill that would require edible or potable marijuana products for sale to be contained in single dose, child-resistant packaging and be labeled with the amount of THC — the active chemical in marijuana — in each dose.
Lawmakers will return to Montpelier for the 2016 session on Jan. 5.